N

6

-methyladenosine (m

6

A) modification is found the most prevalent and abundant post-transcriptional mRNA modification in eukaryotic cells. It regulates almost all stages of RNA life cycle including splicing

translocation

stability

decay and translation. As a dynamic and reversible process

m

6

A modification is catalyzed by the RNA methyltransferases (‘writers’)

removed by the demethylases (‘erasers’)

and interacts with m

6

A-binding proteins (‘readers’). Recent studies have revealed that these m

6

A modification regulators are frequently expressed aberrantly in various types of cancer

and involved in cell proliferation

differentiation

metabolism

particularly

in tumorigenesis and tumor progression through diverse mechanisms. In this review

the m

6

A modification process and its regulatory functions in lung cancer are summarized. Furthermore

the research progress in the inhibitor development of m

6

A modification

and the potential of targeting m

6

A modifying proteins for clinical application are discussed.